Several mechanisms capable of triggering acquired resistance have been described in patients with EGFR-mutated advanced NSCLC, such as EGFR T790M mutation, EGFR C797S mutations, MET amplification, and small-cell transformation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.